Yoichi Arai

1980 ,
(digital rectal examination, DRE),
(PAP) .
(prostate specific
antigen, PSA)
(transrectal ultrasonography, TRUS)

.

. PSA ,
,

. PSA , PAP
1
.
.
PSA , PAP

. , PSA
1)6).

,
PSA
.
PAP
,

.
(AP)
. AP
1936Gutman7)
. AP
,
,
8). , (PAP)

AP 8). 1970
immunoassay ,
radioimmunoassay(RIA) enzymeim-
munoassay (EIA) 9)10). im-
munoassay
, 1980, PSA ,
PAP
. PAP ,

,
11)12).
PSA
PSA
. 34, 000240
4 .
protease kallikrein
13)16). PSAchemotrip-
sin tripsin
17). PSA-
antichemotripsin
, . PSA
,
mg/m1 18),
1)17). PSA
6kilobase , 19

19).
1576
, γ-seminoprotein 21). 1973
Li and Be1ing22)
, EI antigen . 1978
Sensabaugh p30
23). 1979, Rosewll Park Memorial
InstituteWang13)
PAP ,
.
(PSA) .

14)24), PSA
.
1. PSA
Wang13) PSA ,
PSA Ros-
ewl1ParkMemorialInstitute
. 1980 Papsidero25)
,
PSA , PSA
.
(rocket immunoelectrophoresis) ,
PSA 8%
. Kuriyama26),
enzyme immunoassay(EIA) ,
PSA ,
PSA .
PSA cut-off 1. 8ng/ml
. cut-off PSA
(BPH)68% , stage
, A; 63%, B; 79%, C; 77%, D; 86%
.
PSA kit 1984,
Hybritec Tandem-RPSA 27).
Yang radioimmunoassay(RIA)
Pros-Check-PSA 28). ,
.
PSA ,

.
kit PSA ,

1)2)6). 29)
1984 EIKENPA(RIA)
, Kuriyama30)MARKIT-FPA
(EIA) .
PSA
2).
PSA kit10
,
2)6). PSA

. PSA
,
. assay
,
Kuriyama31) .
, PSA
32). 1991
PSA
, PSA
.
, PSA
, PSA
31). , Stamey1992 PSA
,
2). 1994 2
,
.
II. PSA
Oesterlingl) ,
PSA ,
. , , ,
, PSA
.
PSA ,
Tandem-RPSA Pros-CheckPSA

.
Maatman33) PSA
7. 6% ,
. PAP PSA
34). 6)PSA
,
. PSA ,
24 18%
3).
PSA
1577
35), PSA
, 36).
PSA . Stamey3)
Pros-Check PSA , 2. 2±0. 8
. , 0esterling37)Tandem-
RPSA 3. 2±0. 1
. Kabalin38) PSA
,
.
PSA ,
(DRE)
. Brawer39)DRE
, PSA
. Stamey40), DRE PSA
(Pros-CheckPSA)1. 92
. , DRE PSA
Tandem-RPSA randomized study
41). DRE PSA
,
0. 4ng/ml . DRE
PSAcut-off4. Ong/ml
. TRUS PSA
42).

. PA-TESTWAK0 BPH
, DRE PSA
2. 5 43). , MARKIT-
MPA
44). , PSA

45),
6).

PSA .
PSA ,
PSA
42). Yuan42) PSA
. PSA
, 25%
, PSA
, .
PSA 46)47).
PSA
.
III. PSA
PSA
1)2).
Tandem-RPSAPros-Check
PSA .
IMxDainapack(EIA)
48), 49).
PSA EIKEN
PA MARKIT-F PA .
1. cut-off
PSA Cut-off
, .
Tandem-R PSAPros-Check PSA cut-off
, 4. Ong/ml50), 2. 5ng/m13)
. ,
50 2 cut-
off 1. 9ng/m1, 3. 2ng/m1
2). , PSA cut-off ,

, PSA
. MARKIT-FPA
3. 6ng/ml cut-off 30),
MARKIT-MPA
44). EIKEN PA 29)3. 0ng/m1
. , BPH
,
BPH , BPH
cut-off
44)51). PSAcut-off

,
. cut-off

. , TRUS systematic
biopsy ,
52).
, cut-
off .
PSA
51)53)55). PSA
cut-off
52)55). Dalkin55)Tandem-RPSA
PSA
. Tandem-R PSAcut-off4. 0
1578
ng/m160
.
2. BPH PSA
PSA
, BPH PSA
. BPH
775%
1)2)44)51).
cut-off ,
PSA
1)2)6). Oesterling1),
Tandem-RPSA ,
BPHPSA 4 .
BPHPSA4. 0ng/m1
72% , 28% .
BPH PSAcut-off
4. Ong/ml 70%
. BPH
PSA
. Stamey3)Pros-CheckPSA
, BPHlg PSA0. 3ng/ml
. , Weber56)
, 5. 816. 6
, PSA
. ,
, BPH PSA0. 2ng/ml
10ng/ml
57).
, Weber
.
BPHPSA
46)47).
(intraepithelial neo-
plasia) . Brawer58),
Lee59)
, PSA
.
, .
PSA
, 1
. PAP
, PAP PSA
43)51)62)63). stageC
PSA
43)51).
PSA , stageD
90% 62)63). , PSA
, PSA
. PSA
,
,
PSA 64). PSA
PAP
6)30)65).
,
,
.
3. PSAdensity
BPH PSA
,
PSA PSAdensity
(PSAD) 66)67). Benson66)61
1 PSA stage
BPH PSAD .
PSAD0. 1 34 33 ,
0. 050. 111 6 , 0. 05 16 2
, .
, , PSA
, PSAD
2). Rom
mel68), 2, 020
PSAD .
PSAD
, PSA

PSAD . PSAD

, .
4. PSA
, mass
screening( )
. PSA
massscreening
2)30)63). , PSA

,
,
.
systematic biopsy
. 6
(
) , PSA

. , 69) PSA
, PSA
.
PSA
70) 71)
.
,
PSA
72)75). Cooner75)
DRE, PSA, TRUS
,
. PSA
(Tandem-RPSA)cut-off
. PSA4ng/m1 ,
4. 110ng/ml, 10. 1ng/ml , 3
. 1
Cooner75)
. PSAcut-off
TRUS
,
.
5. PSA velocity
Caretr76)
PSA
. BPH
, 826
PSA ,
. ,
PSAvelocity(PSAV)
. PSA
.
, PSAVcut-off 0. 75μ9/1/year
, specificity90%
77). PSAV
BPH
,
.
IV. PSAstaging
Stamey78)
, PSA
(r=0. 7) .
1g PSA3. 5ng/ml
1 (
. , McNeal79)

. PSA patho-
10gicalstage
78)80).
PSA
(2)80). PSA10ng/m1
,
SUrgiCal margin .

PSA
. ,
PSA ,
1)64)80).
Oesterling 1) , cut-off 4ng/ml 10
ng/ml ,
72%, 24% ,
55%, 13% . Stamey81)
, PSA transitionzone

.
PSA
,
.
clinical stage C
82).
PSA
. ,
64)80). Greskovich83),
stageC
PSA 11. 4ng/ml, 11. 2ng/ml
. staging pe1-
vic lymphadenectomy PSA
(MARKIT-F PA), Gleason score
. PSA10ng/ml
Gleason score 6
. , PSA 10ng/ml
Gleason score7 60%
(3)80).
PSAGleasonscore
84). Partin85)703
, PSA(Tandem-R PSA), Gleason score,
pathological stage
,
, .
3 pathological stage
.
Gleason score 5 PSA10. Ong/m1
10% . EIKEN PSA
2 PSA(MARKIT-F PA)pathol0gi-
cal stage( ).
LN, . SV, . CP,
. (80 )
+ Surgical margin
3 PSA(MARKIT-F PA), Gleason score
( 80 )
LN (-) LN (+)
86) , PSA20ng/ml
22
2(9%) .
PSA negative
predictive value .

staging operation87)
PSA
.
PSA
Chybowski88) . 521
, PSA
.
, PSA(Tandem-RPSA)20ng/m1 306
1
. PSA
negativepredictivevalue99. 7%
, PSA
1).
V. PSA
PSA

. PSA , , ,

.
1.
PSA
. ,
, ,
PSA ,

1)57). PSA
, PSA
,

1)37)57)78)89).

PSA . PSA
,
.
,
57)90).
,
90).
,
(2). Tandem. R
, 0esterling37) 0. 07ng/
ml . Hudson90)
, Tandem-R
0. 6ng/m1 .
Pros-Check , 0. 10. 5ng/
ml 1). , ,
,
PSA

. MARKIT M-PA
assay ,
0. 2ng/ml 57).

PSA ,
.
PSA
. ,

PSA
57)78). cut-off
,
. Stamey78)Pros-Check ,
2 PSA cut-off
1582
PSA
, cut. off
0. 3ng/ml . ,
0. 3ng/ml ( )
.
Lange89)Tandem-R 59
, 36 PSA0. 4ng/ml
91% NED ,
. PSA0. 4ng/ml 100%
. Hudson90) Tandem-R
, 89%
0. 6ng/m1 ,
cut-o 0. 6ng/ml
. MARKIT-M PA
, 0. 4ng/m1
cut-off
(2)57).
cut-off .
PSA ,
. Lange
89), Tandem-R cut-off
0. 4ng/m1 ,
1243 ( 23 ) PSA
, .
, PSA
,
8 (4)57). ,
Graves91), Pros-Check
72 assay .
cut-off
0. 1ng/ml , ,
Pros-Check 5
PSA ,
. PSA ,
,
.
PSA
, .
PSA ,
, clinica1
failure PSA "biochemica1
failure" . Frazier92)
, PSAclinical failure
2228( 16) ,
. , 11 PSA 36
clinica1 failure ,
PSA
. bio-
chemical failure
,
.
.
2.
PSA
. PSA

. Stamey93)
183( 5) ,
PSA 11%
, . 82% PSA
1 , 1
8% . 1
51%PSA . Hudson90)
, PSA
17% . Kaplan94)
PSA ,
44% , . D'
4 PSA(MARKIT-M
PA) . assay
(MARKIT-F PA)
( 57 ).
Amico95) biochemical failure92)
PSA .
PSA (PSA doubling time, PSA-
DT)
.
PSA
, PSA
. Link96), PSA
, 60%PSA
, . Hudson97) PSA
(Tandem-RPSA)0. 6ng/ml 21
, 29%1 PSA
, .
,
.
3.
Kuriyama98), Killian28)stageD2
PSA
. PSA
28)98). , 99)
PSA
. PSA

100).
PSA
,
. Stamey
101) PSA
, 6
, . 99) 1
6 PSA nadir
, . Arai100)
, PSA
, 1 PSA
(
3). 102), 7 PSA
50%
, . , PSA

, 103). Csapo104),
,
PSA
. Leo105)
PSA ,
PSA
. Morgan
106),

1 ( 100 )
1584

,
111).
PSA
.
PSA .
VI. PSA
PSA ,

112). ,
, PSA
. Stamey78),
PSA
, , .
Lange113) 5% PSA ,
. Hortin112) 92 3
(3. 3%)PSA1. 0ng/ml ,
.
. PSA
114), PSA
. Graves115)
14% PSA
, . PSA
78).
, Pummer116), stageT3
Pros-Check PSA , 6
, 4 9. 527. Ong/ml
, . 3
Tandem-R
. PSA α-
1-antichemotripsin
45). 116),
PSA , α-1-antichemotripsin
, Pros-Check
1
. , PSA
(MARKIT-M PA)
. MARKIT-M PA2
,
MARKIT-F PA (
). PSA
,
PSA . .
VII. PSA
PSA ,

,
117)119). PSA
. ,
PSA
119). Kamoshida
120)cloaca PSA
, PSA
121).
PSA
,
. Sakai122)PAPPSA
,
PAP , .
, Deguchi123)
,
.
VIII. PSA
PSA ,
.
PSA Tremblay
124) . , PSA BPH
, .

. PSA
38),
PSA
. White125) 77%
PSA ,
,
. , Takayama121)
PSA
. , PSA
PSA
, PSA
, .
PSA
.
IX. PSA
Stenman45), Lilja126) PSA
protaeaseinhibitor α1-
antichemotrypsin(ACT) (PSA-
1585
ACT) .
, PSA, PSA-ACT
,
45)126)127). , BPH PSA
,
PSA-ACT
. , PSA
.
Christensson128)
55% 73%
. 129)PSA-
ACT EIA ,
. γseminoprotein
, assay
PSA
130)131). Demura
131)PSA γ-seminoprotein
, PSA/γ-seminoprotein
.
PSA
, ,
,
, .
X. PSA stage
PSATRUS
, stage
132). ,
DRE PSA

. stageA B
,
. ,
0rgan Systems Coordinating Cen-
ter(OSCC) 133). Stamey
, PSATRUS
stageA , stage TAX
(4)134).
stage
,
.
, Wang13)PSA
10 .
Oesterling1) review ,
priority γSm
. γ-Sm
1985 135),
136).
Shidal1137)
. γ-Sm PSA ,
PSA
136). , γSm PSA

51)63)136)138).
130)138). γ-Sm
assay PSA
,
130)131).
, PSA
. Schaller24)Lundwall14)
, PSA γ-Sm
. 136) ,
PAP 3
,
.


.
, alkaline
phosphatase139>140), LDH141), polyamine142), CEA143)'
4 0SCC ( 134) )
1586
creatinine kinase BB144)145), osteocalcin146)147),
.
,
PSA
. PSAPAP
.

, PSA
. PSA
,
. ,
,
. ,
, ,
PSA ,
. PSA
.
,

.

1) Oesterling, J. E.: Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol., 145, 907-923, 1991.
2) Kuriyama, M.: Prostat-specific antigen as a tumor marker in prostate cancer. Int. J. Urol., 1, 99-113, 1994.
3) Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S. and Redwine, E.: Prostate- specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl. J. Med., 317, 909-916, 1987.
4) Lange, P. H. and Brawer, M. K.: Serum
prostate-specific antigen: Its use in diagnosis and management of prostate cancer. Urology, 33, 13-17, 1989.
5) Brawer, M. K.: Prostate specific antigen. A review. Acta Oncol., 30, 161-168, 1991.
6) , , , :
(
): PSA. , 4, 1065-1072, 1991.
7) Gutman, E. B., Sproul, E. E. and Gutman, A. B.: Significance of increased phosphatase activity of bone at site of osteoblastic metastases secon- dary to carcinoma of the prostate gland. Am. J. Cancer, 28, 485-495, 1936.
8) Pontes, J. E.: Biochemical markers in prostate cancer. J. Urol., 130, 1037-1047, 1983.
9) Cooper, J. F. and Foti, A. G.: A radioim-
munoassay for prostatic acid phosphatase; I. Methodology and range of normal male serum values. Invest. Urol., 12, 98-102, 1974,
10) Lee, C. L., Wang, M. C., Murphy, G. P. and Chu, T. M.: A solid phase fluorescent immunoassay for human prostatic acid phosphatase. Cancer Res., 38, 2871-2878, 1978.
11) Rubenstein, M., Guinan, P. D., McKiel, C. F. and Dubin, A.: A review of acid phosphatatse in the diagnosis and prognosis of prostatic cancer. Clin. Physiol. Biochem., 6, 241-252, 1988.
12) Kontturri, M.: Is acid phosphatase (PAP) still justified in the management of prostate cancer? Acta Oncol., 30, 169-170, 1991,
13) Wang, M. C., Valenzuela, L. A., Murphy, G. P. and Chu, T. M.: Purification of a human pros- tate specific antigen. Invest. Urol., 17, 159-163, 1979.
14) Lundwall, A. and Lilja, H.: Molecular cloning of human prostatic specific antigen cDNA. FEBS, Lett., 214, 317-322, 1987.
15) Chu, T. M., Kawinsky, E., Hibi, N., Croghan, G., Wiley, J., Killian, C. S. and Corral, D.: Prostate-specific antigenic domain of human
prostatespecific antigen identified with mono- clonal antibodies. J. Urol., 141, 152-156, 1989.
16) Lilja, H. A.: A kallikrein-like serine protease in prostatic fluid leaves the predomnant seminal vesicle protein. J. Clin. Invest., 76, 1899-1903, 1985.
17) Ban, Y., Wang, M. C., Watt, K. W., Loor, R. and Chu, T. M.: Proteolytic activity of human prostate-specific antigen. Biochem. Biophys. Res. Commun., 123, 482-488, 1984,
18) Sensabaugh, G. F.: Isolation and characteriza- tion of a semen-specific protein from human seminal plasma: A potential new marker for semen identification. J. Forensic. Sci., 23, 106-109, 1978,
19) Riegmen, P. H. J., Vlietstra, R. J., van der Korper- t, J. A. G. M., Romijin, J. C. and Trapman, J.: Characterization of the prostate-specific antigen gene: A novel human kallikrein-like gene. Biochem. Biophys. Res. Commun., 159, 95-102, 1989.
20) , , , ,
, :
( VII).
, 159, 356, 1989.
21) : “γ-Seminopro-
tein”() ,
. , 44, 529-548, 1974.
22) Li, T. S. and Beling, C. G.: Isolation and char- acterization of two specific antigens of human seminal plasma. Fertil. Steril., 24, 134-137,
1587
1973. 23) Sensabaugh, G. F. and Blake, E. T.: Seminal
plasma protein p30: Simplified purification and evidence for identity with prostate specific antigen. J. Urol., 144, 1523-1526, 1990.
24) Schaller, J., Akiyama, K., Tsuda, R., Hara, M., Marit, T. and Rickli, E. E.: Isolation, charac- terization and amino-acid sequence of y- seminoprotein, a glycoprotein from human sem- inal plasma. Eur. J. Biochem., 170, 111-120, 1987.
25) Papsidero, L. D., Wang, M. C., Valenzuela, L. A., Murphy, G. P. and Chu, T. M.: A prostate antigen in sera of prostate cancer patients. Cancer Res., 40, 2428-2432, 1980.
26) Kuriyama, M., Wang, M. C., Papsidero, L. D., Kil- lian, C. S., Shimano, T., Valenzuela, L. A., Ni- shiura, T., Murphy, G. P. and Chu, T. M.: Quantification of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res., 40, 4658-4662, 1980.
27) Liedtke, R. J. and Batjer, J. D.: Measurement of prostate-specific antigen by radioimmunoas- say. C1in. Chem., 30, 649-652, 1984.
28) Killian, C. S., Yang, N., Emrivh, L. J., Vargas, F. P., Kuriyama, M., Wang, M. C., Slack, N. H., Papsidero, L. D., Murphy, G. P., Chu, T. M. and the Investigators of the National Prostatic Cancer Project: Prognostic importance of
prostate-specific antigen in patients with stage B2 to Dl prostate cancer. Cancer Res., 45, 886-891, 1985.
29) , , , ,
, , , : RIA
(PA) .
, 75, 1982-1988, 1984.
30) Kuriyama, M., Shinoda, I., Takeuchi, T., Ban, Y., Kawada, Y., Nishiura, T., Yoshiki, T., Okada, K., Yoshida, 0., Hamami, G., Kamidono, S., Mita, T. and Terasoma, K.: Clinical evaluation of prostate-specific antigen with an EIA; A co-operative study. Nishinihon
J. Urol., 46, 1431-1438, 1987. 31) Kuriyama, M., Akimoto, S., Akaza, H., Arai,
Y., Usami, M., Imai, K., Tanaka, Y., Yamazaki, H., Kawada, Y., Koiso, K., Yoshida, 0., Kotake, T., Yamanaka, H., Machida, T., Aso, Y. and Shimazaki, J.: Comparison of various assay system for prostate-specific antigen standardi- zation. Jpn. J. Clin. Oncol., 22, 393-399, 1992.
32) Graves, H. C. B., Wehner, N. and Stamey, T. A.: Comparison of a polyclonal and monoclonal immunoassay sor PSA: Need for an interna- tional antigen standard. J. Urol., 144, 1516-1522, 1990.
33) Maatman, T. J.: The role of prostate specific antigen as a tumor marker in men with advanced adenocarcinoma of the prostate. J. Urol., 141, 1378-1380, 1989.
34) Dejter. SW. Jr., Martin, J. S., McPherson, R. A. and Lynch, J. H.: Daily variability in human serum prostate-specific antigen and prostatic acid phosphatase: A comparative evaluation. Urology, 32, 288-292, 1988.
35) Simak, R., Madersbacher, S., Zhang, Z. and Maier, U.: The impact of ejaculation on serum prostate specific antigen. J Urol., 150, 895-897, 1993.
36) Leventhal, E. K., Rozanski, T. A., Morey, A. F. and Rholl, V.: The effect of exercise and activity on serum prostate specific antigen levels. J. Urol., 150, 893-894, 1993.
37) Oesterling, J. E., Chan, D. W., Epstein, J. I., Kim- ball, A. W. Jr., Bruzek, D. J., Rock, R. C., Brend- ler, C. B. and Walsh, P. C.: Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J. Urol., 139, 763-765, 1987.
38) Kabalin, J. N. and Hornberger, J. C.: Prostate- specific antigen is not excreted by human kid- ney or eliminated by routine hemodialysis. Urology, 37, 308-310, 1991.
39) Brawer, M. K., Schifman, R. B., Ahmann, FR., Ahmann, M. E, and Coulis, K.: The effect of digital rectal examination on serum levels of
prostate-specific antigen. Arch. Path. Lab. Med., 112, 1110-1112, 1989.
40) Stamey, T. A.: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of
prostate. Monogr. Urol., 10, 49, 1989. 41) Chybowsky, F. M., Bergstralh, E. J. and Oester-
ling, J. E.: The effect of digital rectal exami- nation on the serum prostate specific antigen concentration: Results of a randomized study.
J. Urol., 148, 83-86, 1992. 42) Yuan, J. J. J., Coplen, D. E., Petros, J. A., Figen-
shau, R. S., Ratliff, T. L., Smith, D. S. and Catalona, W. J.: Effects of rectal examination,
prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J. Urol., 147, 810-814, 1992.
43) Arai, Y., Yoshiki, T., Oishi, K., Takeuchi, H. and Yoshida, 0.: The role of prostatic specific antigen in monitoring prostatic cancer ant its
prognostic importance. Urol. Res., 18, 331-336, 1990.
44) , , , ,
:
(PSA) MARKIT-M PA PSA
588
. , 38, 1129-1134,
1992,
45) Stenman, U. H., Leinonen, L., Afthan, H., Rannik- ko, S., Tuhkanen, K. and Afthan, 0.: A com-
plex between prostate-specific antigen and a 1- antichemotrypsin is the major form of prostate- specific antigen in serum of patients with pros- tatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res., 51, 222-226, 1991.
46) Lindstedt, G., Jacobsson, A., Lundberg, P. A., Hedelin, H., Petterson, S. and Unsgaard, B.: Determination of prostate-specific antigen in serum by immunoradiometric assay. Clin. Chem., 36, 53-58, 1990,
47) Armitage, T. G., Cooper, E. H., Newling, W. W., Rovinson, M. R. G. and Appleyard, I.: The val- ue of the measurement of serum prostate specific antigen in patients with benign pros- tatic hyperplasia and untreated prostate can- cer. Brit. J. Urol., 62, 584-589, 1988.
48) Klee, G. G., Dodge, L. A., Zincke, H. and Oester- ling, J. E.: Measurement of serum prostate specific antigen using IMx prostate specific antigen assay. J. Urol., 151, 94-98, 1994.
49) , , , ,
, , , , ,
, , , ,
, , :
(IMxPADainapack)
1993.
50) Myrtle, J. F.: Normal levels of prostate- specific antigen (PSA). In: Clinical Aspects of Prostate Cancer. Edited by W. J. Catalona, D. S. Coffey and J. P. Karr. New York, Elsevier Sci- ence Publishing Co., p. 183-189, 1989.
51) , , , ,
, , , :

γ-seminoprotein
. , 35,
1519-1528, 1989.
52) Hodge, K. K., McNeal, H. E., Terris, M. K. and
Stamey, T. A.: Random systematic versus dir-
ected ultrasound guided transrectal core biop-
sies of the prostate. J. Urol., 142, 71-75, 1989.
53) Labrie, F., Dupont, Z., Suburu, R., Cusan, L.,
Tremblay, M., Gomez, J. L. and Emond, J.:
Serum prostate specific antigen as pre-
screening test for prostate cancer. J. Urol., 147,
846-852, 1992,
54) Babarian, R. J., Miyashita, H., Evans, E. B. and
Ramirez, El.: The distribution of prostate
specific antigen in men withour cninical or
pathological evidence of prostate cancer: Rela- tionship to gland volume and age. J. Urol., 147, 837-840, 1992,
55) Dalkin, B. L., Ahmann, F. R. and Kopp, J. B.: Prostate specific antigen levels in men older than 50 years without clinical evidence of pros- tatic carcinoma. J. Uro1., 150, 1837-1839, 1993.
56) Weber, J. P., Oesterling, J. E., Peters, C. A., Par- tin, A. W., Chan, D. W. and Walsh, P. C.: The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia. J. Urol., 141, 987-992, 1989,
57) Arai, Y., Ohnishi, H., Oishi, K., Takeuchi, H. and Yoshida, 0.: Use of a new hypersensitive assay for the detection of prostate specific antigen in prostate cancer. Jpn. J. Clin. Oncol., 23, 110-115, 1993,
58) Brawer, M. K.: Prostatic intraepitherial neo- plasia and prostate-specific antigen. Urology, 34, 62-65, 1989,
59) Lee, F., Torp-Pederson, ST., Caroll, J. T., Siders, D. B., Christensen-Day, C. and Mitchell, A. E.: Use of transtrectal ultrasound and
prostate-specific antigen in diagnosis of pros- tatic intraepithelial neoplasia. Urology, 34, 4-8, 1989,
60) Guinan, 0., Bhatti, R. and Ray, P.: An evalua- tion of prostate specific antigen in prostatic cancer. J. Urol., 138, 1181-1184, 1987.
61) , , , ,
, , , , ,
, , , ,
, : DELFIAPSA
PSA . , 38, 425-431,
1992.
62) Stamey, T. A. and Kabalin, J. N.: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated
patients. J. Urol., 141, 1070-1075, 1989. 63) Arai, Y., Yoshiki, T., Okada, K. and Yoshida,
0.: Multiple marker evaluation in prostatic cancer using prostatic specific antigen, gamma- seminoprotein and prostatic acid phosphatase. Urol. Int., 44, 135-140, 1989,
64) Partin, A. W., Carter, H. B., Chan, D. W., Epstein, J. I., Oesterling, J. E., Rock, R. C., Weber, J. P. and Walsh, P. C.: Prostet specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia. J. Urol., 143, 747-752, 1990,
65) , , , :
(PA) .
, 34, 636-642, 1988.
K., Kaplam, S. A., Olsson, C. A. and Cooner, W.
H. G.: Postate specific antigen density: A
means of distinguishing benign prostatic hyper-
trophy and prostate cancer. J. Urol., 147,
815-816, 1992,
67) Benson, M. C., Whang, IS., Olsson, C. A., McMa-
hon, D. J. and Cooner, W. H.: The use of pros-
tate specific antigen density to enhance the
predictive value of intermediate levels of serum
prostate specific antigen. J. Uro1., 147, 817-821,
1992.
68) Rommel, F. M., Agusta, V. E., Breslin, J. A.,
Huffnagle, H. W., Pohl, CE., Sieber, OR. and
Stahl, C. A.: The use of prostate specific
antigen and prostate specific antigen density in
the diagnosis of prostate cancer in a community
based urology practice. J. Urol., 151, 88-93,
1994.
: (PSA)
. , 42, 539-543,
1994,
:
71) , :
. , 84, 1175-1187, 1993.
72) Brawer, M. K., Chetner, M. P., Beatie, J., Buch- ner, D. M., Vessella, R. L. and Lange, P. H.: Screenig for prostatic carcinoma with prostate specific antigen. J. Urol., 147, 841-845, 1992,
73) Cooner, W. H., Mosley, B. R., Rutherford, C. L. Jr., Beard, J. H., Pond, H. S., Bass, R. B. Jr. and Terry, W. J.: Clinical application of tran- srectal ultrasonography and prostate specific antigen in the search for prostate cancer. J. Urol., 139, 758-761, 1988,
74) Cooner, W. H., Mosley, B. R., Rutherford, CL. Jr., Beard, J. H., Pond, H. S., Bass, R. B. Jr., Terry, W. J., Igel, T. C. and Kidd, D. D.: Prostate can- cer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J. Urol., 143, 1146-1154, 1990,
75) Cooner, W. H.: Prostate-specific antigen, digi- tal rectal examinaton, and transrectal ultra- sonic examination of the prostate in prostate cancer detection. Monogr. Urol., 12, 1-13, 1991,
76) Carter, H. B., Morrell, C. H., Pearson, J. D., Brant, L. J., Plato, C. C., Metter, E. J., Chan, D. W., Fozard, J. L. and Walsh, P. C.: Estimation of
prostatic growth using serial prostate-specific antigen measurements in men with and without
prostate disease. Cancer Res., 52, 3323-3328, 1992,
77) Carter, H. B., Pearson, J. D., Metter, E. J., Brant, L. J., Chan, D. W., Andres, R., Fozard, J. L. and Walsh, P. C.: Longitudinal evaluation of
prostate-specific antigen levels in men with and eithout prostate disease. J. A. M. A., 267, 2215-2220, 1992,
78) Stamey, T. A., Kabalin, J. N., McNeal, J. E., Jo- hnstone, LM., Freiha, F., Redwine, E. A. and Yang, N.: Prostate specific antigen in the diag- nosis and treatment of adenocarcinoma of the
prostate. II. Radical prostatectomy treated patients. J. Urol., 141, 1976-1083, 1989,
79) McNeal, J. E., Bostwick, D. G., Kindrachuk, R. A., Redwine, E. A., Freiha, F. S. and Stamey, T. A.: Patterns of progression in prostate can- cer. Lancet, 1, 60-63, 1986.
80) Arai, Y., Yoshiki, T., Yamabe, H. and Yoshida, 0.: Value of prostate-specific antigen mea- surements in predicting lymphnode involve- ment in prostate cancer. Urol. Int., 45, 356-360, 1990,
81) Stamey, T. A., Dietrick, D. D. and Issa, M. M.: Large organ confined, impalpable tranzition zone prostate cancer: Association with metas- tatic levels of prostate specific antigen. J. Urol., 149, 510-515, 1993.
82) , , , ,
, : StageD1
stageD1
. , 35, 981-986, 1989.
83) Greskovich, F. J. III, Johnson, D. E., Tenney, D.
M. and Stephenson, R. A.: Prostate specific
antigen in patients with clinical stage C pros-
tate cancer: Relation to lymph node status and
grade. J. Urol., 145, 798-801, 1991.
84) , : .
KARKINOS, 4, 1163-1169, 1991, 85) Partin, A. W., Yoo, J., Carter, H. B., Pearson, J.
D., Chan, D. W., Epstein, J. I. and Walsh, P. C.: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol., 150, 110-114, 1993.
86) , , , ,
, :
. , 84, 2124-2130, 1993.
87) , , , ,
, :
. , 38, 419-424,
1992,
88) Chybowski, F. M., Keller, J. J. L., Bergstralh, E. J.
1590
and Oesterling, J. E.: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other clinical
parameters. J. Urol., 145, 313-318, 1991, 89) Lange, P. H., Ercole, C. J., Lightner, D. J., Fraley,
E. E. and Vessella, R.: The value of prostate specific antigen determinations before and after radical prostatectomy. J. Urol., 141, 873-879, 1989,
90) Hudson, M. A., Bahnson, R. R. and Catalona, W. J.: Clinical use of prostate specific antigen in patients with prostate cancer. J. Urol., 142, 1011-1017, 1989.
91) Graves, H. C. B., Wehner, N. and Stamey, T. A.: Ultrasensitive radioimmunoassay of prostate- specific antigen. Clin. Chem., 38, 735-742, 1992,
92) Frazier, H. A., Robertson, J. E., Humphrey, P. A. and Paulson, D. F.: Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J. Urol., 149, 516-518, 1993.
93) Stamey, T. A., Kabalin, J. N. and Ferrari, M.: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients. J. Urol., 141, 1084-1087, 1989,
94) Kaplan, I., Prestidge, B. R., Cox, R. S. and Bag- shaw, MA.: Prostate specific antigen after irradiation for prostatic carcinoma. J. Urol., 144, 1172-1176, 1990,
95) D'Amico, A. V. and Hanks, G. E.: Linear re-
gressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer, 72, 2638-2643, 1993,
96) Link, P., Freiha, F. S. and Stamey, T. A.: Ad-
juvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy. J. Urol., 145, 532-534, 1991,
97) Hudson, M. A. and Catalona, W. J.: Effect of adjuvant radiation on prostate speciffc antigen following radical prostatectomy. J. Urol., 143, 1174-1177, 1990.
98) Kuriyama, M., Wang, M. C., Lee, C. L., Killian, C. S., Papsidero, L. D., Inaji, H., Loor, R. M., Lin, M. F., Nishiura, T., Slack, N. H., Murphy, G. P. and Chu, T. M.: Use of human prostate specific antigen in monitoring prostate cancer. Cancer Res., 41, 3874-3878, 1981.
99) , , , ,
: D2
, γ
. , 36,
783-791, 1990. 100) Arai, Y., Yoshiki, T. and Yoshida, 0.: Prog-
nostic significance of prostate specific antigen in endocrine treatment for prostate cancer. J. Urol., 144, 1415-1419, 1990.
101) Stamey, T. A., Kabalin, J. N., Ferrari, M. and Yang, N.: Prostate specific antigen in the diag- nosis and treatment of adenocarcinoma of the
prostate. IV. Antiandrogen treated patients. J. Urol., 141, 1084-1087, 1989.
102) :
Prostate-specific
antigen(pA)PAP γ-Sm .
, 25, 2627-2639, 1990.
103) Montgomery, B. T., Young, C. Y. -F., Bilhartz, D. L., Anderews, P. E., Prescott, J. L., Thompson, N. F. and Tindall, D. J.: Hormonal regulation of
prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate, 21, 63-73, 1992,
104) Csapo, Z., Brank, K., Walther, R. and Fokas, K.: Comparative experimental study of the serum
prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice. J. Urol., 140, 1032-1038, 1988,
105) Leo, M. E., Bilhartz, D. L., Bergstralh, E. J. and Oesterling, J. E.: Prostate specific antigen in hormonally treated stage D2 prostate cancer: Is it always an accurate indicator of disease sta- tus? J. Urol., 145, 802-806, 1991,
106) Morgan, W. R., Zincke, H., Rainwater, L. M., Myers, R. P, and Klee, G. G.: Prostate specific antigen values after radical retropubic pros- tatectomy for adenocarcinoma of the prostate: Impact of adjuvant treatment (hormonal and radiation). J. Urol., 145, 319-323, 1991.
107) , , , ,
, :
(PSA) . 82
, p. 245, 1994.
:
. , 84, 450-456, 1993.
109) , , , ,
, , :
(DWA2114R) .
, 38, 897-902, 1992.
110) Seidman, A. D., Scher, HI., Petrylak, D., Der- shaw, D. D. and Curley, T.: Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J. Urol., 147, 931-934, 1992.
111) , :
. , 46, 999-1003, 1992.
1591
112) Hortin, G. L., Bahnson, R. R., Daft, M., Chan, K. -M., Catalona, W. J. and Ladenson, J. H.: Differences in values obtained with 2 assays of
prostate specific antigen. J. Uro1., 139, 762-765, 1988,
113) Lange, P. H.: Editorial comments. J. Urol., 148, 23, 1992,
114) Tepper, S. L., Jagirdar, J., Heath, D. and Geller, S. A.: Homology between the female paraur- ethral (Skene's) glands and the prostate, im- munohistochemical demonstration. Arch. Path. ol. Lab. Med., 108, 423-425, 1984,
115) Graves, H. C. B.: Noise control in solid-phase immunoassays by use of a matrix coat. J. Im- munol. Methods, 111, 167-178, 1988.
116) Pummer, K., Wirnsberger, G., Purstner, P., Stett- ner, H. and Wandschneider, G.: False positive
prostate specific antigen values in the sera of woman with renal cell carcinoma. J. Urol., 148, 21-23, 1992,
117) Nadji, M., Tabei, S. Z., Castro, A., Chu, T. M., Wang, M. C., Murphy, G. P. and Morales, A. R.: Prostatic specific antigen: An immunohis- tologic marker for prostatic neoplasia. Cancer, 48, 1229-1232, 1981,
118) Tell, D. T., Khoury, J. M., Taylor, H. G. and Veasey, S. P.: Atypical metastasis from pros- tate cancer: Clinical utility of the immunoper- oxidase technique for prostate-specific antigen. J. A. M. A., 253, 3574-3575, 1985,
119) Ford, T. F., Butcher, D. N., Masters, JR. and Parkinson, M. C.: Immunocytochemical locali- zation of prostate-specific antigen: Specificity and application to clinical practice. Br. J. Urol., 57, 50-55, 1985,
120) Kamoshida, S. and Tsutsumi, Y.: Extrapros- tatic localization of prostatic acid phosphatase and prostate-specific antigen: Distinction in cloacogenic glandular epithelium and sex- dependent expression in human anal gland. Hum. Pathol., 21, 1108-1111, 1990,
121) Takayama, T. K., Vessella, R. L., Brawer, M. K., True, L. D., Noteboom, J. and Lange, P. H.: Urinary prostate specific antigen levels after radical prostatectomy. J. Urol., 151, 82-87, 1994,
122) Sakai, H., Yogi, Y., Minami, Y., Yushita, Y., Kanetake, H. and Saito, T.: Prostate specific antigen and prostatic acid phosphatase im- munoreactivity as prognostic indicator of advanced prostatic carcinoma. J, Urol., 149, 1020-1023, 1993,
123) Deguchi, T., Doi, T., Ehara, H., Ito, S., Takaha- shi, Y., Nishino, Y., Fujihiro, S., Kawamura, T., Komeda, H., Hone, M., Kaji, M., Shimokawa,
K., Tanaka, T. and Kawada, Y.: Detection of micrometastatic prostate cancer cell in lymphnode by reverse transcriptase-polymerase chain reaction. Cancer Res., 53, 5350-5354, 1993,
124) Temblay, J., Frenette, G., Tremblay, R. R., Dupont, A., Thabet, M. and Dube, J. U.: Excre- tion of three major prostatic scretory proteins in the urine of normal men and patients with benign prostatic hypertrophy or prostate can- cer. Prostate, 10, 235-243, 1987.
125) White, R. W. D., Meyers, F. J., Soares, S. D. E., Miller, D. G. and Soriani, T. F.: Urinary pros- tate specific antigen levels: Role in monitoring the response of prostate cancer to therapy. J. Urol., 147, 947--951, 1992,
126) Lilja, H., Christensson, A., Dahlen, U., Mati- kainen, M. -T., Nilsson, 0., Pettersson, K. and Lobgren, T.: Prostate-specific antigen in serum occurs predominantly in complex with a-l-antichemotrypsin. Clin. Chem., 37, 1618-1625, 1991.
127) Wood, W. G., Sloot, van der E. and Bohle, A.: The establishment and evaluation of luminescent-labelled immunometric assay for
prostate-specific antigen for prostate-specific antigen- a-l-antichemotrypsin complexes in serum. Eur. J. Clin. Chem. Clin. Biochem., 29, 787-794, 1991,
128) Christensson, A., Bjork T., Nilsson, 0., Dahlen, U., Matikainen, M. -T., Cockett, A. T. K., Abra- hamsson, P. -A. and Lilja, H.: Serum prostate- specific antigen complexed to a-1- antichemotrypsin as an indicator of prostate cancer. J. Urol., 150, 100--105, 1993.
129) , , , ,
, , , , ,
: PSA-ACT
free PSA rate .
, 28, 1409, 1993.
130) , , , :
. Medical Tribune,
26, 34-35, 1993.
131) Demura, T., Watarai, Y., Togashi, M., Hirano, T., Ohashi, N. and Koyanagi, T.: Measure- ment of prostate specific antigen and y- seminoprotein ratio: A new means of distin-
guishing benign prostatic hyperplasia and pros- tate cancer. J. Urol., 150, 1740-1745, 1993.
132) : , Frontier;
(PSA) . Medicament
News, 1435, 18-19, 1994. 133) Catalona, W. J. and Whitmore, W. F.: New
staging systems for prostate cancer. J. Urol., 142, 1302-1304, 1989.
1592
134) Stamey, T. A. and McNeal, J. E.: Adenocar- cinoma of the prostate. in Campbell's Urology, 6th ed., Edited by Walsh, P. C., Retik, A. B., Stamey, T. A. and Vaughan, E. D., vol. 2, sec. IX, chapt. 29, p. 1159-1221, 1992.
135) , , , ,
, , , , ,
, , , , ,
, :
(γ-seminopr0tein)
136) , , :
( ): γ-Sm. , 4,
1079-1082, 1991,
137) Siddall, J. K., Shetty, S. D. and Cooper, E. H.:
Measurement of serum y-seminoprotein and
prostate specific antigen evaluated for monitor- ing carcinoma of the prostate. Clin. Chem., 32,
2040-2043, 1986.
138) , , , ,
, , , , ,
: γ-seminoproteinpr0state-
specific antigen
. , 82, 541-550, 1991.
139) Wajsman, Z., Chu, T. M., Bross, D., Saroff, J., Murphy, G. P., Johnson, D. E., Scott, W. W., Gib- bons, R. P., Prout, CR. and Schmidt, J. D.: Clinical significance of serum alkaline phos-
phatase isoenzyme levels in advanced prostatic carcinoma. J. Urol., 119, 244-246, 1978.
140) Killian, CS., Vargas, F. P., Pontes, E. J., Beckley, S., Slack, N. H., Murphy, G. P. M, Chu, T. M. and Investigators of the National Prostatic Cancer Project's Cooperative Clinical Trials: The use of serum isoenzymes of alkaline and acid phos- phatase as possible quantitative markers of
tumor load in prostate cancer. Prostate, 2, 187-206, 1981,
141) Grayhack, J. T., Lee, C., Kolbusz, W. and Oliver, L.: Detection of carcinoma of the prostate utilizing biochemical observations. Cancer, 45, 1896-1901, 1980,
142) Cohen, S. S.: Conference on polyamines in cancer. Cancer Res., 37, 939-942, 1977,
143) Neufeld, L., Dubin, A., Guinan, P., Nabong, R., Ablin, R. J. and Bush, I. M.: Carcinoembryonic antigen in the diagnosis of prostate carcinoma. Oncology, 29, 376-381, 1974,
144) Zweig, M. H. and Van Steirteghem, A. C.: Assessment by radioimmunoassay of serum creatine kinase BB (CK-BB) as a tumor marker: Studies in patients with various cancer and a comparison of CK-BB cncentrations to
prostate acid phosphatase concentrations. J. Natl. Cancer Inst., 66, 859-862, 1981,
145) Huber, P. R., Zaugg, T., Linder, E., Hagmaier, V. and Rutishauser, G.: Creatinine kinase isoenzyme (CK-BB) in combination to prostatic acid phosphatase measured by RIA in the diag- nosis of prostatic cancer. Urol. Res., 10, 75-80, 1982.
146) Tarle, M., Kovacici, K. and Strelkov-Alfirevic, A.: Correlation between bone scan and serum levels of osteocalcin, prostate-specific antigen, and prostatic acid phosphatase in monotoring
patients with disseminated cancer of the pros- tate. Prostate, 15, 211-219, 1989,